Abstract
Purpose To develop and evaluate an automated segmentation and classification tool for the discrimination of neoplastic and non-neoplastic intracerebral hemorrhage (ICH) on admission Computed Tomography (CT) utilizing images containing hemorrhage and perihematomal edema.
Materials and Methods The models were developed and evaluated using a retrospective dataset of patients who presented with acute ICH of unknown cause upon admission, using CT scans obtained from a single institution between January 2016 and May 2020 for both training and testing. Etiology of ICH were binarized into non-neoplastic and neoplastic ICH according to follow-up MRI results based on the ATOMIC ICH classification. Masks for ICH and PHE were manually segmented. Two separate models were trained: 1) An nnU-Net segmentation model 2) A ResNet-34 classification model. An end-to-end tool was evaluated by concatenating the two models which allowed the segmentation model to preprocess the images for the classification model. Performance enhancement was assessed by fine-tuning the model on a randomly selected, small subset of the external cohort. To assess the model’s generalizability, the performance was additionally validated on an external dataset. Evaluation metrics were accuracy (Acc), area under the curve (AUC) and corresponding sensitivities and specificities.
Results A total of 291 patients were included of whom 116 (39.86%) presented with neoplastic and 175 (60.14%) with non-neoplastic ICH. The end-to-end classification tool achieved an Acc of 86% and an AUC of 85% with a sensitivity and specificity of 80% and 93% in the test set. On the external validation cohort (n=58), the classification pipeline achieved an AUC of 68% and Acc of 66% (sensitivity 64%; specificity 67%). Fine-tuning on a selected small subset of the external cohort enhanced performance, achieving an AUC and accuracy of 70% (sensitivity 70%; specificity 71%).
Conclusion An end-to-end classification tool achieved a high diagnostic performance and generalizability in classifying neoplastic from non-neoplastic ICH on CT, suggesting a robust framework for a potential clinical implementation as a decision-aided tool in early ICH management.
Competing Interest Statement
Tobias Penzkofer reports research agreements (no personal payments, outside of submitted work) with AGO, Aprea AB, ARCAGY-GINECO, Astellas Pharma Global Inc. (APGD), Astra Zeneca, Clovis Oncology, Inc., Dohme Corp, Holaira, Incyte Corporation, Karyopharm, Lion Biotechnologies, Inc., MedImmune, Merck Sharp, Millennium Pharmaceuticals, Inc., Morphotec Inc., NovoCure Ltd., PharmaMar S.A. and PharmaMar USA, Inc., Roche, Siemens Healthineers, and TESARO Inc., and fees for a book translation (Elsevier). All other authors have no relevant financial or non-financial interests to disclose.
Funding Statement
The authors declare that no funds or other support were received during the preparation of this manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee of Charité Berlin, Germany [protocol number EA1/035/20] gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The datasets that support the findings of our study are available upon reasonable request from the corresponding author.
